- Home
- PCF vs XGN Comparison
PCF vs XGN Comparison
Compare PCF & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCF | XGN |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.1M | 110.7M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PCF | XGN |
|---|---|---|
| Price | $4.96 | $7.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.29 |
| AVG Volume (30 Days) | 120.0K | ★ 349.0K |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.02 |
| Revenue Next Year | N/A | $10.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.92 | $2.59 |
| 52 Week High | $6.31 | $12.23 |
Technical Indicators
Market Signals| Indicator | PCF | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 30.63 | 40.92 |
| Support Level | $4.95 | $6.83 |
| Resistance Level | $5.12 | $8.94 |
| Average True Range (ATR) | 0.06 | 0.56 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 26.61 | 6.83 |
Price Performance
Historical ComparisonAbout PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective mainly by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.